Efeito da associa????o das terapias com lazer de baixa pot??ncia (LBP) e c??lulas- tronco mesenquimais derivadas de tuba uterina humana sobre a inflama????o pulmonar em modelo experimental de doen??a pulmonar obstrutiva cr??nica (DPOC)

• Ano de defesa: 2013
• Autor(a) principal: Silva, Vanessa Roza da
• Orientador(a): Oliveira, Ana Paula Ligeiro de
• Banca de defesa: Carvalho, Fl??vio Aimbire Soares de , Vieira, Rodolfo de Paula
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Nove de Julho
• Programa de Pós-Graduação: Programa de P??s-Gradua????o em Biofot??nica Aplicada ??s Ci??ncias da Sa??de
• Departamento: Sa??de
• País: Brasil
• Palavras-chave em Português: DPOC; laser de baixa pot??ncia; c??lulas-tronco mesenquimais; inflama????o pulmonar; citocinas
• Palavras-chave em Inglês: COPD; low level laser; mesenchymal stem cells; lung inflammation; cytokines
• Área do conhecimento CNPq: CIENCIAS DA SAUDE
• Link de acesso: http://bibliotecatede.uninove.br/handle/tede/1129

Currently the Chronic Obstructive Pulmonary Disease (COPD) has a high prevalence and a high economic and social cost. In this context, several experimental models have been proposed, aiming at the discovery of new therapeutic approaches. Accordingly, the use of mesenchymal stem cells (MSC) is an innovative and accessible treatment of pulmonary acute and chronic disease, as they have important therapeutic potentials (immunoregulation, anti-fibrogenic, inducing proliferation of tissue progenitor cells, anti-apoptotic and pro-angiogenic and chemoattraction). Therapy with low levellaser (LLL) is a relatively new effective therapy, with very low cost and no side effects. In this project we aim to study some parameters in animals with COPD undergoing therapies with LLL (15 days before the experiment) and MSC obtained from human fallopian tube (administered 2 times: 15 days and 7 days before the experiment). The protocol used for the induction of COPD consists in submitting C57BL/6 mice for 75 days (2 times / day) to inhaled cigarette smoke. On day 76ththe animals were sacrified and structural and functional parameters of lungs were evaluated. Our results indicate that the treatment with LLL and MSC greatly reduces lung inflammation (as demonstrated through BAL cell counting and histomorphometric analysis in lung parenchyma), BAL pro-inflammatory cytokines (IL-1??, IL-6, IL-10, TNF-?? and KC) and the lung expression of NF-???B, NFAT and IL-10. Furthermore, these therapies also reduced airway mucus secretion and collagen deposition.